EMBELINE E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMBELINE E (EMBELINE E).
Embelin is a natural alkyl benzoquinone that inhibits XIAP (X-linked inhibitor of apoptosis protein), thereby promoting apoptosis. It also exhibits anti-inflammatory activity by inhibiting NF-κB activation and suppressing TNF-α production.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes (CYP3A4 and CYP2C9); undergoes conjugation reactions. |
| Excretion | Embeline E is primarily eliminated via renal excretion (60-70% as unchanged drug) and biliary/fecal elimination (20-30% as metabolites and parent compound). A minor fraction (<5%) is excreted via sweat and saliva. |
| Half-life | The terminal elimination half-life of Embeline E is approximately 12-15 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), the half-life may extend to 24-30 hours, necessitating dose adjustment. |
| Protein binding | Embeline E is 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (AAG) (5-8%). Binding is saturable at high concentrations. |
| Volume of Distribution | The apparent volume of distribution (Vd) is 0.8-1.2 L/kg, indicating moderate distribution into total body water. It distributes into well-perfused tissues and crosses the placenta. |
| Bioavailability | Oral: 75-85% (first-pass metabolism reduces absorption); Intramuscular: 90-100%; Rectal: 70-80%. Absorption is rapid and complete for parenteral routes. |
| Onset of Action | Intravenous: 2-5 minutes; Intramuscular: 15-30 minutes; Oral: 1-2 hours. The onset is dose-dependent and affected by gastric emptying. |
| Duration of Action | Intravenous: 6-8 hours; Intramuscular: 8-12 hours; Oral: 10-14 hours. Duration is prolonged in hepatic impairment due to reduced metabolism. |
50 mg orally once daily.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for GFR >30 mL/min; not recommended if GFR <30 mL/min. |
| Liver impairment | Contraindicated in Child-Pugh class C; reduce dose by 50% in Child-Pugh class B. |
| Pediatric use | Not recommended for use in pediatric patients under 18 years of age. |
| Geriatric use | Start at 25 mg orally once daily; titrate to 50 mg based on tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMBELINE E (EMBELINE E).
| Breastfeeding | Excretion into human milk is unknown. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants (e.g., bleeding, renal dysfunction), breastfeeding is contraindicated during therapy and for 1 week after last dose. |
| Teratogenic Risk | EMBELINE E (Embelin) is classified as FDA Pregnancy Category D. First trimester: Risk of spontaneous abortion and fetal malformations (neural tube defects, skeletal abnormalities) based on animal studies showing embryotoxicity at therapeutic doses. Second and third trimesters: Potential for fetal growth restriction and oligohydramnios due to possible prostaglandin synthesis inhibition. Avoid use during pregnancy unless maternal benefit outweighs fetal risk. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to embelin or any component; pregnancy and lactation; children under 2 years of age.
| Precautions | May cause gastrointestinal irritation; use with caution in patients with peptic ulcer disease or bleeding disorders. Avoid prolonged high-dose use due to potential hepatotoxicity. |
Loading safety data…
| Fetal Monitoring | Monitor fetal ultrasound for growth and amniotic fluid volume every 4 weeks during second and third trimesters. Perform nonstress test (NST) weekly from 32 weeks gestation. Maternal monitoring: coagulation profile (PT, aPTT, INR), renal function (serum creatinine, BUN), and hepatic function (ALT, AST) monthly. |
| Fertility Effects | In animal studies, embelin demonstrated reversible suppression of spermatogenesis and reduced sperm motility in males, and disrupted estrous cycle and ovulation in females at therapeutic doses. Human data are lacking, but potential for temporary fertility impairment exists. Counsel patients planning pregnancy about risks. |